About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Veronique Birault

Board Observer

Veronique is the Director of Translation at the Francis Crick Institute. Since she joined the Crick in 2015, Veronique has established translational science capabilities and an operational structure to enable a diverse portfolio of translatable projects. She has enabled 11 spin-outs to translate Crick science into patient benefit across cell therapy, vaccines, medical technology and small molecule therapeutics, with overall investment to date over £1 billion.

Veronique has 20 years' drug discovery and development experience in industry. She led multidisciplinary research teams and provided strategic leadership on translational work and clinical research programmes. She led the allergic inflammation discovery performance unit at GSK.